分子生物标志物对临床生存结局的意义因结肠癌侧别而异。

The Significance of Molecular Biomarkers on Clinical Survival Outcome Differs Depending on Colon Cancer Sidedness.

机构信息

Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan

出版信息

Anticancer Res. 2020 Jan;40(1):201-211. doi: 10.21873/anticanres.13941.

DOI:10.21873/anticanres.13941

PMID:31892568

Abstract

BACKGROUND/AIM: This retrospective study focused on the correlation between molecular markers and prognostic outcomes of colon cancer patients depending on sidedness.

MATERIALS AND METHODS

A total of 117 stage I-III colon cancer patients who underwent colectomy were enrolled. Novel methylation markers (KIF1A, PAX5 and VGF) were selected for epigenetic evaluation and p53 and ERCC1 protein expression was examined for the investigation of genetic alterations.

RESULTS

High frequency of methylation was observed in 68.2% of right-sided and 39.7% of left-sided colon cancer cases (p=0.004). Abnormal p53 was identified in 52.3% of right-sided and 75.3% of left-sided cases (p=0.015). In right-sided cases, highly methylated genes demonstrated significantly favorable disease-free survival (p=0.049). Regarding left-sided cases, advanced T stage (p=0.028) and abnormal p53 (p=0.028) were revealed to be significant predictive factors of the disease-free survival outcome.

CONCLUSION

Molecular alterations, as significant prognostic factors, might differ depending on the sidedness of colon cancers.

摘要

背景/目的：本回顾性研究重点关注分子标志物与结肠癌患者预后结局的相关性，同时考虑肿瘤的发生部位。

材料与方法

共纳入 117 例接受结肠切除术的 I-III 期结肠癌患者。选择新型甲基化标志物（KIF1A、PAX5 和 VGF）进行表观遗传学评估，并检测 p53 和 ERCC1 蛋白表达以研究基因改变。

结果

右侧结肠癌和左侧结肠癌中甲基化高频的发生率分别为 68.2%和 39.7%（p=0.004）。右侧结肠癌和左侧结肠癌中异常 p53 的发生率分别为 52.3%和 75.3%（p=0.015）。在右侧结肠癌中，高度甲基化基因与无病生存显著相关（p=0.049）。对于左侧结肠癌，较深的 T 分期（p=0.028）和异常 p53（p=0.028）是无病生存的显著预测因素。